William Blair research analyst Matt Phipps was quoted in MedCity News following Bristol Myers Squibb’s acquisition of Mirati Therapeutics. Phipps weighed in on the target of the acquisition, cancer drug Krazati.
Equity Research
Matt Phipps Highlights Impact of Acquisition by Bristol Myers Squibb in MedCity News
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
-
-
Vertiv Holdings Co.: Initiation of Research Coverage
William Blair initiated research coverage of Vertiv Holdings Co. (VRT $130.87), a global leader in the manufacturing, design, and servicing of critical digital infrastructure for data centers, communication networks, and commercial and industrial end-markets.